Synthesis and evaluation of novel heterocyclic inhibitors of GSK-3
- 15 April 2006
- journal article
- research article
- Published by Elsevier BV in Bioorganic & Medicinal Chemistry Letters
- Vol. 16 (8), 2091-2094
- https://doi.org/10.1016/j.bmcl.2006.01.057
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- 4-Acylamino-6-arylfuro[2,3-d]pyrimidines: potent and selective glycogen synthase kinase-3 inhibitorsBioorganic & Medicinal Chemistry Letters, 2004
- Novel pyrazolopyrimidine derivatives as GSK-3 inhibitorsBioorganic & Medicinal Chemistry Letters, 2004
- Discovery and Development of GSK3 Inhibitors for the Treatment of Type 2 DiabetesCurrent Pharmaceutical Design, 2004
- Challenges and opportunities with glycogen synthase kinase-3 inhibitors for insulin resistance and Type 2 diabetes treatmentExpert Opinion on Investigational Drugs, 2003
- Selective Glycogen Synthase Kinase 3 Inhibitors Potentiate Insulin Activation of Glucose Transport and Utilization In Vitro and In VivoDiabetes, 2003
- The Structure of Phosphorylated GSK-3β Complexed with a Peptide, FRATtide, that Inhibits β-Catenin PhosphorylationStructure, 2001
- The renaissance of GSK3Nature Reviews Molecular Cell Biology, 2001
- Glycogen Synthase Kinase-3: Properties, Functions, and RegulationChemical Reviews, 2001
- Synthesis of some pyrrolo[2,3-d]pyrimidine and 1,2,3-triazole isonucleosidesTetrahedron, 1997
- C-nucleoside studies. Part 21. Synthesis of some hydroxyalkylated pyrroloand thieno-[3,2-d]pyrimidines related to known antiviral acyclonucleosidesJournal of the Chemical Society, Perkin Transactions 1, 1991